These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 34727399)

  • 1. Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis.
    Zangani C; Giordano B; Stein HC; Bonora S; D'Agostino A; Ostinelli EG
    Hum Psychopharmacol; 2021 Nov; 36(6):e2801. PubMed ID: 34727399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amisulpride versus amineptine and placebo for the treatment of dysthymia.
    Boyer P; Lecrubier Y; Stalla-Bourdillon A; Fleurot O
    Neuropsychobiology; 1999; 39(1):25-32. PubMed ID: 9892856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs versus placebo for dysthymia.
    Lima MS; Moncrieff J
    Cochrane Database Syst Rev; 2000; (4):CD001130. PubMed ID: 11034701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of drugs versus placebo for the treatment of dysthymia.
    Lima MS; Moncrieff J
    Cochrane Database Syst Rev; 2000; (2):CD001130. PubMed ID: 10796749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.
    Montgomery SA
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S9-15; discussion S16-7. PubMed ID: 12685917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis.
    de Lima MS; Hotoph M; Wessely S
    Psychol Med; 1999 Nov; 29(6):1273-89. PubMed ID: 10616934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.
    Zhu Y; Krause M; Huhn M; Rothe P; Schneider-Thoma J; Chaimani A; Li C; Davis JM; Leucht S
    Lancet Psychiatry; 2017 Sep; 4(9):694-705. PubMed ID: 28736102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia.
    Wu J; Kwan AT; Rhee TG; Ho R; d'Andrea G; Martinotti G; Teopiz KM; Ceban F; McIntyre RS
    Expert Rev Clin Pharmacol; 2023; 16(11):1085-1092. PubMed ID: 37864424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study.
    Amore M; Jori MC;
    Int Clin Psychopharmacol; 2001 Nov; 16(6):317-24. PubMed ID: 11712619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on amisulpride.
    Green B
    Curr Med Res Opin; 2002; 18(3):113-7. PubMed ID: 12094819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
    Gao K; Muzina D; Gajwani P; Calabrese JR
    J Clin Psychiatry; 2006 Sep; 67(9):1327-40. PubMed ID: 17017818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of second-generation antipsychotics on anxiety/depression in patients with schizophrenia: A systematic review and meta-analysis.
    Abdolizadeh A; Hosseini Kupaei M; Kambari Y; Amaev A; Korann V; Torres-Carmona E; Song J; Ueno F; Koizumi MT; Nakajima S; Agarwal SM; Gerretsen P; Graff-Guerrero A
    Schizophr Res; 2024 Aug; 270():11-36. PubMed ID: 38843584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators.
    Ravizza L
    J Psychopharmacol; 1999; 13(3):248-54. PubMed ID: 10512080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the treatment of dysthymia: a narrative review.
    Mathias L; Quagliato LA; Carta MG; Nardi AE; Cheniaux E
    Expert Rev Neurother; 2024 Jul; 24(7):633-642. PubMed ID: 38805342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.